Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
ADvantage Therapeutics General Information
The company's lead compound AD04™ is in confirmatory Phase 2b clinical trials in Europe and the UK for early Alzheimer's Disease patients. In previous trials, AD04™ demonstrated statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups, as well as slower decline in hippocampal volume as a biomarker.
Contact Information
Drug Pipeline
AD04
Phase 2Key Partnerships
Longevitytech.fund
ADvantage Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Sep 29, 2025 | $2.5M | Completed | Phase 2 |
To view ADvantage Therapeutics's complete valuation and funding history, request access »